was downgraded at J.P. Morgan to neutral. See limited upside potential, even with an expected UAL merger, J.P. Morgan said.
(MAR - Get Report)
was initiated at BMO Capital Markets with a market perform rating. $41 price target. North America is not a bad place to be, BMO said.
was initiated at Lazard Capital Markets with a buy rating. $15 price target. A bounty of attractive late stage programs, Lazard Capital Markets said.
was initiated at Credit Suisse with an outperform rating. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class, Credit Suisse said.
was downgraded at Goldman Sachs from neutral to sell. Company will likely be hurt by lower demand for high-tech dental equipment, Goldman said.
was upgraded at Citigroup to buy from neutral. $17 price target. Elevated propane to propylene spread seems sustainable given warm weather, Citigroup said.
was downgraded at Credit Suisse from neutral to underperform. Valuation call, based on a $6 price target, Credit Suisse said.
Principal Financial Group
was downgraded at Sterne Agee to neutral from buy. Valuation call, Sterne Agee said.
was downgraded at Jefferies downgraded to hold from buy. Limited upside on Eylea, Jefferies said.
was downgraded at Goldman Sachs from buy to neutral. Valuation call, based on a $67 price target, Goldman Sachs said.
was upgraded at Morgan Stanley to overweight. $25 price target. Visibility is improving, and the company offers the best risk/reward in the industry, Morgan Stanley said.
(UAL - Get Report)
was downgraded at J.P. Morgan to neutral. Valuation call, based on a $30 price target, J.P. Morgan said.
was initiated with a neutral rating at UBS. $22 price target. Attractive secular exposure, but fully valued shares, UBS said.
was downgraded at Lazard Capital Markets to neutral. Company is likely facing a transition year, Lazard Capital Markets said.
was downgraded at Robert Baird from outperform to neutral. Valuation call, based on a $77 price target, Robert Baird said.
STOCK COMMENTS / EPS CHANGES
estimates, target reduced at Nomura. Shares of AAPL now seen reaching $530. Estimates also cut, given lower expected iPhone sales. Neutral rating.
target raised at Credit Suisse to $124, according to Credit Suisse. Survey suggests that dealers are meeting sales forecasts. Outperform rating.
target raised at Jefferies to $13, Jefferies said. LBO is a possibility. Hold rating.
cut from Conviction Buy List at Goldman. Valuation call, based on an $83 price target.
St. Jude Medical
numbers raised at Jefferies. Shares of STJ now seen reaching $39, Jefferies said. Estimates also raised on ending of near- term pressure from Riata/Durata. Hold rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on